ASCO Annual Meeting | Conference

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 14th 2020

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Cancer Mortality Rate Declined More Steeply in States That Expanded Medicaid Under the Affordable Care Act

May 14th 2020

The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t following the passage of the Affordable Care Act of 2010, a study found.

Video Conference Visits Effective in Reducing Stress, Anxiety in Caregivers for Patients with Cancer

May 14th 2020

The use of video conference technology significantly reduced anxiety and stress among individuals who provide care for an individual with cancer and live more than one hour away from the patient.

Integrated Geriatric Assessment Optimizes Care for Older Adults with Cancer

May 13th 2020

Integration of a comprehensive geriatric assessment with geriatrician-led management care improved health-related quality of life, unplanned hospital admissions, and treatment discontinuation among older adults undergoing systemic therapy for their cancer.

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 13th 2020

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Maintenance Therapy with Olaparib Extends Survival in Relapsed, BRCA+ Ovarian Cancer

May 13th 2020

Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.

Larotrectinib Effective in TRK+ Pediatric Cancers and CNS Tumors

June 7th 2019

The efficacy of larotrectinib is supported in distinct patient populations with TRK fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.

Neratinib Combo Improves PFS in HER2+ Breast Cancer

June 6th 2019

Neratinib combined with capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who received at least 2 prior lines of HER2-targeted therapy.

Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer

June 5th 2019

Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.

Margetuximab Superior to Trastuzumab on PFS in HER2-Positive Metastatic Breast Cancer Carriers of CD16A-F Allele

June 5th 2019

Margetuximab, a novel Fc-engineered HER2-targeted antibody, improved progression-free survival compared with trastuzumab in patients with pretreated HER2-positive metastatic breast cancer in the open-label phase III SOPHIA clinical trial.

Acalabrutinib Combo Induces High Responses in CLL

June 5th 2019

Simultaneous targeting of Bruton’s tyrosine kinase and the CD20 antigen led to overall responses in more than 90% of patients with chronic lymphocytic leukemia, including untreated and relapsed/refractory disease.

Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer

June 4th 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the phase III SOPHIA trial of margetuximab plus chemotherapy versus trastuzumab (Herceptin) plus capecitabine in patients with HER2-positive metastatic breast cancer after prior anti–HER2-targeted therapies.

Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma

June 4th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit in Gustave Roussy Cancer Center, Villejuif-Paris, France, discusses results of a 5-year analysis evaluating the long-term effects of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Olaparib Extends PFS, Hits High Response in Confirmatory BRCA+ Ovarian Cancer Trial

June 4th 2019

The PARP inhibitor olaparib reduced the risk of disease progression or death by 38% versus chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA1/2-mutated ovarian cancer who received at least 2 prior lines of chemotherapy.

Chemo-Free Combo Significantly Improves PFS in Previously Untreated CLL

June 4th 2019

The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.

Niraparib/Bevacizumab Combo Active in Recurrent Ovarian Cancer

June 4th 2019

A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.

New Therapies Intriguing for Elusive Targets in NSCLC

June 4th 2019

Two new therapies are showing encouraging findings for patients with NSCLC with either RET rearranged or EGFR exon 20 insertions, raising hope that 2 hard-to-target driver alterations may soon have an associated targeted treatment.

Dr. Richardson on Isatuximab Triplet Regimen in Relapsed/Refractory Myeloma

June 4th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discussed the phase III ICARIA-MM trial, which looked at the triplet regimen of isatuximab, pomalidomide (Pomalyst), and dexamethasone in patients with relapsed/refractory multiple myeloma.

AMG 510 Active in KRAS+ NSCLC

June 4th 2019

The investigational KRASG12C inhibitor AMG 510 achieved a 50% response rate in patients with KRASG12C-positive advanced non–small cell lung cancer, according to results from a phase I study presented at the 2019 ASCO Annual Meeting.

Dr. Petrylak on Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma

June 4th 2019

Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancers, discusses the phase II EV-201 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

NEXT PAGE
PREVIOUS PAGE